Northern Trust Corp Increases Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Northern Trust Corp raised its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 12.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 354,622 shares of the company's stock after purchasing an additional 40,093 shares during the quarter. Northern Trust Corp owned 1.06% of TransMedics Group worth $22,111,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Atlas Capital Advisors Inc. acquired a new position in TransMedics Group during the 4th quarter worth about $31,000. Hager Investment Management Services LLC acquired a new position in shares of TransMedics Group in the fourth quarter worth approximately $33,000. Sachetta LLC bought a new stake in TransMedics Group in the fourth quarter valued at approximately $40,000. AlphaQuest LLC acquired a new stake in TransMedics Group during the 4th quarter valued at approximately $52,000. Finally, Arcadia Investment Management Corp MI bought a new position in TransMedics Group during the 4th quarter worth approximately $72,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently issued reports on TMDX shares. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Piper Sandler reissued an "overweight" rating and issued a $125.00 price objective (up from $105.00) on shares of TransMedics Group in a research note on Friday, May 9th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Oppenheimer lifted their target price on TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, TransMedics Group currently has an average rating of "Moderate Buy" and a consensus target price of $126.70.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 6,000 shares of the business's stock in a transaction on Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director now owns 732 shares of the company's stock, valued at $84,641.16. The trade was a 89.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX traded down $0.23 during trading on Friday, reaching $121.58. 966,002 shares of the stock traded hands, compared to its average volume of 1,355,739. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The stock has a market capitalization of $4.11 billion, a P/E ratio of 129.34 and a beta of 1.91. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a 50-day moving average of $82.91 and a 200-day moving average of $75.67.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company's revenue was up 48.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.35 earnings per share. Analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.